Phase I study of intracarotid administration of carboplatin.

Fifteen patients were treated in a Phase I study of intracarotid carboplatin (200-400 mg/m2) in 5% dextrose and water infused over 15 to 30 minutes through a transfemoral catheter with a 0.2-micron inline filter. This study was done because intravenous carboplatin has less neurotoxicity than cisplatin and is active against brain tumors.

[Value of rapid acquisition cadences synchronized with the electrocardiogram for the diagnosis of pulmonary embolism by digital subtraction angiography].

Pulmonary digital subtraction angiography was performed in 130 patients referred with possible pulmonary emboli. Findings were interpreted as a function of apparatus used (acquisition cadence, size of matrix, ECG synchronization) and of site of injection (peripheral or central). It now appears possible to diagnose pulmonary embolism with satisfactory reliability in 80 to 85% of cases.